MAP2K7 and acute lymphoblastic leukemia: Furthermore, knockdown of the MAPK/ERK pathway activator, mitogen-activated protein kinase kinase (MEK), in glucocorticoid-resistant B-ALL cell lines restored drug sensitivity [71].